U.S. Patent Office Pushes India To Reverse Compulsory Licensing Policy
This article was originally published in PharmAsia News
Executive Summary
Pressed at a House hearing, PTO Deputy Director Rea testifies “we have somebody on the ground right now … who constantly engages” Indian authorities in order to prevent another Nexavar-like compulsory license.